CEO Interviews

More Interviews

Genetic Technologies (NASDAQ: GENE)

Genetic Technologies: Expanding Portfolio of Disease Risk Tests

Genetic Technologies (Nasdaq: GENE) is a diversified molecular diagnostics company developing tools for the prediction and assessment of cancer risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class.

 Play

Medalist Diversified (NASDAQ: MDRR)

Medalist Diversified REIT: Restarted Dividend Payments in Q2 2021

Medalist Diversified REIT (NASDAQ: MDRR) was founded in 2003 as a private equity company specializing in acquiring, owning, and managing commercial real estate in the Southeast. The Company’s strategy is to focus on value-add and opportunistic commercial real estate which is expected to provide an attractive balance of risk and returns. Medalist utilizes a rigorous, consistent, and replicable process for sourcing and conducting due diligence of acquisitions.

 Play

Recruiter.com (OTCQB: RCRT)

Recruiter.com: Transforming the Recruiting Industry for the Digital Economy

Recruiter.com (OTCQB: RCRT) is a hiring platform for the world’s largest network of recruiters. Recruiter.com empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology. The Recruiter.com network of over 25,000 small and independent recruiters utilize an innovative web platform, complete with AI-driven job matching, screening and video interviewing (Summer 2020) to recruit talent faster.

 Play

BioVie (NASDAQ: BIVI)

BioVie: Near-Term Catalysts from Phase 2 & Phase 3 Trials

BioVie (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.

 Play

Milestone Scientific (NYSE AMERICAN: MLSS)

Milestone Scientific: New Innovations in Injection Technologies

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications.

 Play

Greenwich LifeSciences (NASDAQ: GLSI)

Greenwich LifeSciences: Phase 3 Targeting Recurrent Breast Cancer

Greenwich LifeSciences (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. In a prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites) Phase IIb clinical trial led by MD Anderson, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up.

 Play

Esports Entertainment Group (NASDAQ:GMBL)

CEO interview with Esports Entertainment: Projecting $100M+ Revenue Over Next 12 Months

Esports Entertainment Group is a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Its mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together.

 Play

Can-Fite BioPharma (NYSE American: CANF)

Can-Fite BioPharma: Robust Pipeline Includes 75% Enrolled Phase 3 Psoriasis Program

Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH.

 Play

Annovis Bio (NYSE American: ANVS)

Annovis Bio: Potential Game Changer for Alzheimer’s Treatment

Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport.

 Play

Tiziana Life Sciences (NASDAQ: TLSA)

Tiziana Life Sciences: Robust Pipeline with Multiple Near-Term Catalysts

Tiziana Life Sciences (NASDAQ: TLSA) CEO & CSO, Dr. Kunwar Shailubhai, discusses the Company’s planned spinoff of StemPrintER and the launch of its new COVID-19 trial in Brazil. Tiziana is a dual-listed clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma.

 Play

Lantern Pharma (NASDAQ: LTRN)

Lantern Pharma: Transforming Cancer Drug Development with A.I.

Lantern Pharma (NASDAQ: LTRN) is a clinical stage biotechnology company focused on innovating the cancer drug development process by rescuing and repositioning drug candidates that others have tried, but failed, to develop and developing new drugs of its own using advanced genomics and artificial intelligence (“AI”). Lantern leverages advances in machine learning, genomics and artificial intelligence by using a proprietary AI platform to discover biomarker signatures aimed at helping identify patients more likely to respond to our pipeline of cancer therapeutics.

 Play


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market